Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (321-330 of 566) with videos related to

Pageof 57
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosisTaxiarchis V Kourelis, Shaji K Kumar, Morie A Gertz, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2016
Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal GammopathiesLarissa S Higgins, Ronald S Go, David Dingli, et al.
Cancer Research|April 6, 2007
Molecular dissection of hyperdiploid multiple myeloma by gene expression profilingWee J Chng, Shaji Kumar, Scott Vanwier, et al.
American Journal of Hematology|November 13, 2014
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosisGregory P Kaufman, Angela Dispenzieri, Morie A Gertz, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple MyelomaSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Cancer|June 29, 2019
Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysisRonan W Hsieh, Ronald S Go, Jithma P Abeykoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Survival and years of life lost in different age cohorts of patients with multiple myelomaHeinz Ludwig, Vanessa Bolejack, John Crowley, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
American Journal of Hematology|February 4, 2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Eli Muchtar, M Hasib Sidiqi, et al.
The Lancet Regional Health. Western Pacific|June 19, 2025
Imaging in plasma cell disorders-consensus recommendations of the Asian myeloma network bone imaging workgroupChandramouli Nagarajan, Natasha Fay Anthony, Jens Hillengass, et al.
Pageof 57

Showing results (321-330 of 566) with videos related to

Sort By:
Pageof 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosisTaxiarchis V Kourelis, Shaji K Kumar, Morie A Gertz, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2016
Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal GammopathiesLarissa S Higgins, Ronald S Go, David Dingli, et al.
Cancer Research|April 6, 2007
Molecular dissection of hyperdiploid multiple myeloma by gene expression profilingWee J Chng, Shaji Kumar, Scott Vanwier, et al.
American Journal of Hematology|November 13, 2014
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosisGregory P Kaufman, Angela Dispenzieri, Morie A Gertz, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple MyelomaSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
Cancer|June 29, 2019
Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysisRonan W Hsieh, Ronald S Go, Jithma P Abeykoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Survival and years of life lost in different age cohorts of patients with multiple myelomaHeinz Ludwig, Vanessa Bolejack, John Crowley, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
American Journal of Hematology|February 4, 2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Eli Muchtar, M Hasib Sidiqi, et al.
The Lancet Regional Health. Western Pacific|June 19, 2025
Imaging in plasma cell disorders-consensus recommendations of the Asian myeloma network bone imaging workgroupChandramouli Nagarajan, Natasha Fay Anthony, Jens Hillengass, et al.
Pageof 57